How to Diagnose Coccidioidomycosis
Use a multi-test diagnostic strategy combining serological testing (the primary method), culture/microscopy, and antigen testing, as no single test has adequate sensitivity to rule out disease. 1
Primary Diagnostic Approach: Serological Testing
Serology is the most common diagnostic method and should be performed first in all patients with suspected coccidioidomycosis. 1
Serological Test Characteristics and Timeline:
- IgM antibodies appear within 1–3 weeks of symptom onset 1
- IgG antibodies develop later at 4–8 weeks after symptom onset 1
- Available commercial tests include EIA (enzyme immunoassay), immunodiffusion (ID), and complement fixation (CF), each with different sensitivity and specificity profiles 1
- Initial testing algorithm: Start with EIA, followed by confirmatory ID or CF testing 2
- Quantitative CF testing should be repeated approximately every 12 weeks during treatment to monitor therapeutic response 1
Important Serological Caveats:
- Cross-reactivity with other fungal infections occurs, requiring careful interpretation in context of clinical presentation and imaging 2
- Serological testing can wane over time and may become negative after successful treatment 2
- False negatives and false positives do occur 2
Microbiological Confirmation (Gold Standard but Low Sensitivity)
Culture of Coccidioides species from any clinical site provides definitive diagnosis but has low sensitivity. 1
Culture Specifications:
- Grows on routine blood agar and Sabouraud dextrose agar at 25–30°C 1
- Mycelial growth visible as early as 4–5 days, but cultures should be held for up to 6 weeks 1
- Critical safety note: Coccidioides is highly infectious in the laboratory and requires biosafety level 2 or 3 precautions 3
Direct Microscopy and Histopathology:
- Identification of spherules or endospores in clinical specimens is considered proven disease, even without positive culture 1
- Standard fungal stains (KOH, hematoxylin-eosin, Grocott methenamine-silver) should be used on respiratory specimens, BAL fluid, or tissue biopsies 1, 3
- Direct visualization is more rapid than culture but still has low sensitivity 2
Antigen Testing (Particularly for Immunocompromised Patients)
Coccidioidal antigen testing via EIA is available for both urine and serum and is especially helpful in highly immunocompromised patients. 1
Antigen Test Performance:
- Overall sensitivity of 70.8% in confirmed cases, with specificity of 97.8% 2
- Higher sensitivity in severe and disseminated disease, particularly among immunosuppressed patients (79.2% of positive cases) 2
- Serum and urine antigen testing are complementary—some samples positive in one but not the other 2
- Cross-reactivity with other endemic fungal pathogens occurs in approximately 10% of cases 2
- Less sensitive than Histoplasma antigen testing but still clinically useful 2
Recommended Diagnostic Algorithm
In patients with appropriate geographic exposure and compatible illness, use multiple diagnostic tests simultaneously rather than relying on a single method. 2
Comprehensive Testing Strategy:
- Direct visualization and culture of sputum, BAL, or biopsy material 2
- Serum antibody testing (IgM and IgG via EIA, ID, or CF) 2
- Urine and serum antigen testing, especially in immunocompromised patients 2
- Chest radiograph in all patients—look for dense infiltrates (often upper lobe) with hilar or mediastinal adenopathy 1
Special Considerations for CNS Disease:
- CSF sample should be obtained from all patients with suspected meningitis (sustained headache or CNS symptoms) 1
- Meningitis is a particularly morbid complication requiring aggressive diagnostic evaluation 1
Clinical Context Matters
The diagnostic approach should be tailored based on:
- Severity of illness: Severe disease warrants more aggressive sampling including bronchoscopy or tissue biopsy 2
- Immune status: Immunocompromised patients benefit most from antigen testing 2
- Test availability: Coccidioides-specific antigen testing is performed only at select reference laboratories 2